| MDL | MFCD18782653 |
|---|---|
| Molecular Weight | 607.62 |
| Molecular Formula | C35H28F3N5O2 |
| SMILES | O=C1N(C2=C(C=C1)C=NC3=CC=C(C=C32)C4=CC5=CC=CC=C5N=C4)C6=CC=C(C(C(F)(F)F)=C6)N7CCN(CC7)C(CC)=O |
|
mTOR 3 nM (IC 50 ) |
mTORC1 2-10 nM (IC 50 ) |
mTORC2 2-10 nM (IC 50 ) |
ATM 0.6 μM (IC 50 ) |
DNA-PK 1 μM (IC 50 ) |
PI3K-α 1.8 μM (IC 50 ) |
hVps34 3 μM (IC 50 ) |
||||||
|
Autophagy |
||||||||||||
Torin1 (250 nM) completely inhibits proliferation and causes a G1/S cell cycle arrest, and decreases cell size to a greater degree than 50 nM rapamycin in wild-type MEFs [1] . Torin1 has more than 800-fold selectivity between mTOR and PI3Kis, and is very selective relative to other PIKK family kinases with the exception of DNA-PK [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Torin1 (20 mg/kg, i.p.) is efficacious in a U87MG xenograft model, and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 2 mg/mL ( 3.29 mM ; ultrasonic and warming and heat to 60°C)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6458 mL | 8.2288 mL | 16.4577 mL |
| 5 mM | --- | --- | --- |
| 10 mM | --- | --- | --- |
Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 0.25 mg/mL (0.41 mM); Clear solution
Add each solvent one by one: 1% DMSO >> 99% saline
Solubility: 0.05 mg/mL (0.08 mM); Suspended solution; Need ultrasonic